

Table S1 Front-line treatment of DOC plus RAM

	N (%)
Chemotherapy	115 (48.5)
Platinum doublets	53 (22.4)
Platinum doublets plus bevacizumab	42 (17.7)
Monotherapy	20 (8.4)
EGFR inhibitors	27 (11.4)
Erlotinib	4 (1.7)
Afatinib	6 (2.5)
Osimerutinib	17 (7.2)
Immunotherapy (monotherapy)	80 (33.7)
Nivolumab	52 (21.9)
Pembrolizumab	16 (6.8)
Atezolizumab	10 (4.2)
Durvalumab	2 (0.8)
Chemotherapy plus immunotherapy	13 (5.5)
Pembrolizumab	9 (3.8)
Atezolizumab	4 (1.7)
Experimental therapy	2 (0.9)

DOC, docetaxel; RAM, ramucirumab; EGFR, epidermal growth factor receptor.

**Table S2** Univariate and multivariate analysis of OS in patients treated with DOC plus RAM

Factor	Univariate analysis		Multivariate analysis	
	HR (95% CI)	P value	HR (95% CI)	P value
Age				
<75	1		NA	
≥75	1.13 (0.70–1.84)	0.610	NA	NA
Sex				
Male	1		NA	
Female	0.74 (0.53–1.04)	0.087	NA	NA
ECOG-PS				
0–1	1		1	
2–4	2.37 (1.64–3.42)	0.001	2.02 (1.37–2.97)	0.001
Smoking status				
Non-smoker	1		1	
Smoker	1.57 (1.06–2.34)	0.025	1.61 (1.06–2.45)	0.026
MPE				
(–)	1		1	
(+)	1.76 (1.25–2.47)	0.001	1.63 (1.15–2.31)	0.007
Lung metastasis				
(–)	1		1	
(+)	0.97 (0.70–1.35)	0.862	1.03 (0.73–1.45)	0.869
Liver metastasis				
(–)	1		1	
(+)	1.46 (0.96–2.23)	0.075	1.23 (0.79–1.90)	0.356
Brain metastasis				
(–)	1		1	
(+)	1.27 (0.88–1.82)	0.198	1.30 (0.91–1.87)	0.153

OS, overall survival; DOC, docetaxel; RAM, ramucirumab; ECOG-PS, Eastern Cooperative Oncology Group-performance status; MPE, malignant pleural effusion; HR, Hazard Ratio; CI, confidence interval.